These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 17118245)

  • 21. Prophylactic human papillomavirus vaccination: a breakthrough in primary cervical cancer prevention.
    Garcia FA; Saslow D
    Obstet Gynecol Clin North Am; 2007 Dec; 34(4):761-81, ix. PubMed ID: 18061868
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Programmatic issues in the implementation of an HPV vaccination program to prevent cervical cancer.
    Ault K; Reisinger K
    Int J Infect Dis; 2007 Nov; 11 Suppl 2():S26-8. PubMed ID: 18162242
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The GARDASIL vaccine can prevent cervical carcinoma caused by human papilloma virus (HPV) (results from our participation and from the study carried out in Greece).
    Ansstasiou-Fotaki P; Deligeoroglou E; Kreatsas G
    Akush Ginekol (Sofiia); 2007; 46(3):17-20. PubMed ID: 18018777
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Knowledge of cervix cancer, human papilloma virus (HPV) and HPV vaccination at the moment of introduction of the vaccine in women in Belgium.
    Donders GG; Gabrovska M; Bellen G; Van Keirsbilck J; Van Den Bosch T; Riphagen I; Verjans M
    Arch Gynecol Obstet; 2008 Apr; 277(4):291-8. PubMed ID: 17965870
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Decreasing risk: impact of HPV vaccination on outcomes.
    Hymel PA
    Am J Manag Care; 2006 Dec; 12(17 Suppl):S473-83. PubMed ID: 17203991
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Progress toward implementation of human papillomavirus vaccination--the Americas, 2006-2010.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2011 Oct; 60(40):1382-4. PubMed ID: 21993342
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potential barriers to HPV vaccine provision among medical practices in an area with high rates of cervical cancer.
    Keating KM; Brewer NT; Gottlieb SL; Liddon N; Ludema C; Smith JS
    J Adolesc Health; 2008 Oct; 43(4 Suppl):S61-7. PubMed ID: 18809147
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Writing for PRO position: Should the HPV vaccine be mandatory for early adolescent girls?
    Cruise E
    MCN Am J Matern Child Nurs; 2007; 32(4):208. PubMed ID: 17667281
    [No Abstract]   [Full Text] [Related]  

  • 29. The new human papillomavirus (HPV) vaccine: pros and cons for pediatric and adolescent health.
    Thomas TL
    Pediatr Nurs; 2008; 34(5):429-31. PubMed ID: 19051848
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Introducing human papillomavirus vaccines into the health system in South Africa.
    Botha MH; Dochez C
    Vaccine; 2012 Sep; 30 Suppl 3():C28-34. PubMed ID: 22939017
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Human papillomavirus vaccination. Consensus Conference in pediatric age].
    Bartolozzi G; Bona G; Ciofi M; De Martino M; Di Pietro P; Duse M; Esposito S; Gasparini R; Mariani L; Marostica G; Paravati F; Plebani A; Principi N; Zuccotti GV; Tovo PA
    Minerva Pediatr; 2007 Jun; 59(3):165-82. PubMed ID: 17519861
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Human papillomavirus vaccines].
    Brun JL
    J Gynecol Obstet Biol Reprod (Paris); 2008 Feb; 37 Suppl 1():S155-66. PubMed ID: 18187268
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reducing patient risk for human papillomavirus infection and cervical cancer.
    Herbert J; Coffin J
    J Am Osteopath Assoc; 2008 Feb; 108(2):65-70. PubMed ID: 18303060
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Benefits, cost requirements and cost-effectiveness of the HPV16,18 vaccine for cervical cancer prevention in developing countries: policy implications.
    Goldie SJ; O'Shea M; Diaz M; Kim SY
    Reprod Health Matters; 2008 Nov; 16(32):86-96. PubMed ID: 19027626
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Protecting the next generation: what is the role of the duration of human papillomavirus vaccine-related immunity?
    Günther OP; Ogilvie G; Naus M; Young E; Patrick DM; Dobson S; Duval B; Noël PA; Marra F; Miller D; Brunham RC; Pourbohloul B
    J Infect Dis; 2008 Jun; 197(12):1653-61. PubMed ID: 18513154
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Screening and vaccination: two synergic tools for the prevention of cervical cancer].
    Zaratti L; Senatore S; Franco E
    Ig Sanita Pubbl; 2007; 63(4):449-57. PubMed ID: 17912281
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cervical cancer prevention in the human papilloma virus vaccine era.
    Ghazal-Aswad S
    Ann N Y Acad Sci; 2008 Sep; 1138():253-6. PubMed ID: 18837904
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Writing for CON position: Should the HPV vaccine be mandatory for early adolescent girls?
    Anderson TL
    MCN Am J Matern Child Nurs; 2007; 32(4):209. PubMed ID: 17667282
    [No Abstract]   [Full Text] [Related]  

  • 39. Attitudes toward HPV vaccination among parents of adolescent girls in Mysore, India.
    Madhivanan P; Krupp K; Yashodha MN; Marlow L; Klausner JD; Reingold AL
    Vaccine; 2009 Aug; 27(38):5203-8. PubMed ID: 19596420
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Human papillomavirus and the HPV vaccine: are the benefits worth the risks?
    Knudtson M; Tiso S; Phillips S
    Nurs Clin North Am; 2009 Sep; 44(3):293-9. PubMed ID: 19683091
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.